# Treatment methods for mesothelioma
Mesothelioma is an aggressive cancer whose treatment depends on the stage, location (pleura, peritoneum, or other membrane) and the patient's overall health. The approaches described here are used at various stages of the disease and are aimed at slowing growth, relieving symptoms, and where possible extending life.
Surgery
ProveniIncluded in official guidelines, or approved by EMA or FDA
Surgical removal of the affected membrane and surrounding tumors is a central pillar of treatment, especially in earlier stage disease. The procedure may largely concern the lung lining (pleura), abdominal lining (peritoneum), or the heart lining (pericardium). Surgeons aim to remove as much tumor tissue as possible while sparing vital organs.
Commonly used procedures include:
- **Pleurectomy/decortication**: removal of the damaged lung lining without removing the lung itself
- **Extrapleural pneumonectomy (EPP)**: removal of the lung lining, the lung itself, the diaphragm, and the heart lining on the affected side
- **Cytoreductive surgery**: in peritoneal mesothelioma, where tumor areas are removed
The procedure itself is demanding and requires recovery of several weeks to months. Possible complications include infection, bleeding, thrombosis (clots), and shortness of breath. Many patients undergo surgery in combination with chemotherapy and/or radiation.
Chemotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Chemotherapy is a standard treatment and is often given before, after, or alongside surgery. Different types of chemotherapy can be used:
**Platinum-based regimens** (for example cisplatin or carboplatin combined with pemetrexed) are the most commonly used first-line treatments. These drugs disrupt DNA synthesis in cancer cells, preventing them from dividing and growing.
Common side effects of chemotherapy include nausea, fatigue, hematotoxicity (low blood cell counts), alopecia (hair loss), and neuropathy (nerve damage, usually in feet and hands). Severity varies greatly from person to person. Many side effects are reversible after treatment stops.
In peritoneal mesothelioma, chemotherapy is sometimes injected directly into the abdominal cavity (intraperitoneal chemotherapy), where the drug acts directly on the tumor area.
Radiotherapy (radiation)
ProveniIncluded in official guidelines, or approved by EMA or FDA
External radiation can be used at the site of the tumor, especially in combination with surgery and chemotherapy. Targeted radiation fields focus on known tumor tissue. Radiotherapy works by causing DNA damage to rapidly dividing cells.
Commonly used forms are conventional 3D radiotherapy, intensity-modulated radiotherapy (IMRT), and in some centers stereotactic radiation therapy (SBRT) for localized disease.
Side effects may include: skin redness and irritation, fatigue, sometimes more severe side effects such as lung inflammation (pneumonitis) or damage to the heart or esophagus, depending on the irradiated area. These side effects can sometimes appear months after treatment.
Immunotherapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Checkpoint inhibitors (for example nivolumab and ipilimumab) activate the immune system to recognize and attack cancer cells. These drugs block signals by which tumor cells can disable lymphocytes.
Nivolumab alone or in combination with ipilimumab is approved for unresectable or metastatic mesothelioma. Combinations of immunotherapy can be more effective than monotherapy, but also cause more side effects.
**Side effects** of checkpoint inhibitors are immune-related adverse events (irAEs): auto-immune inflammations that can affect almost any organ system, such as colitis (bowel inflammation), hepatitis, pneumonitis (lung inflammation), and endocrine disorders. These can be serious and sometimes require steroids and treatment interruption. The higher the dose and the more combinations, the greater the risk.
Multimodal treatment
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients undergo a combination of surgery, chemotherapy and radiotherapy, tailored to tumor size and location. Examples include:
- **Neoadjuvant chemotherapy** (before surgery) to shrink the tumor
- **Adjuvant treatment** (after surgery) to address remaining disease
- **Induction chemotherapy followed by surgery and adjuvant radiotherapy** in certain protocols
This multimodal approach is more complex and requires coordination of multiple specialists, but provides better outcomes in earlier stage disease.
Supportive care (symptom management)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Since mesothelioma can cause pain, coughing, shortness of breath and fluid accumulation (effusion), supportive measures are essential:
- **Pleural drainage** or **talc pleurodesis** (sealing of the pleural membrane) to reduce fluid accumulation in the lung
- **Pain relief** and respiratory system support
- **Physiotherapy** and rehabilitation after major procedures
- **Psychosocial support** for patient and loved ones
This focuses on quality of life and manageability of symptoms alongside tumor-directed treatment.
Experimental approaches in clinical studies
ResearchediPositive results in clinical studies, not yet standard treatment
A number of newer strategies are being investigated in clinical trials:
- **TEAD inhibitors** (for example AZ4331): these block the Hippo signaling pathway, which is hyperactive in many mesotheliomas. Studies are ongoing.
- **IDE892 and other MTAP inhibitors**: targeting specific genetic abnormalities in mesothelioma cells
- **Proteasome inhibitors** (e.g. SHY-ONC6): disrupt protein degradation in cancer cells
- **Topoisomerase I inhibitors** (for example rintatolimod sesutecan): disrupt DNA repair
- **Personalized immunochemotherapy testing** with organoid platforms: customized combinations based on individual tumor characteristics
These treatments are not yet in standard practice. They are being tested because preliminary research shows promise.
Genetic biomarkers and treatment choice
ResearchediPositive results in clinical studies, not yet standard treatment
Research into tumor DNA and proteins (e.g. BAP1 loss, MTAP deletion, cGAS expression) increasingly helps doctors understand which patients respond better to certain treatments. This is not yet a routine standard for all patients, but is being investigated in study settings and is slowly beginning to enter clinical practice, especially for immunotherapy and experimental drugs.
Treatment of symptoms in non-resectable or metastatic mesothelioma
ProveniIncluded in official guidelines, or approved by EMA or FDA
If surgery is not possible, the focus is on immunotherapy (nivolumab with or without ipilimumab) or chemotherapy (platinum-containing) to slow growth. Supportive care (fluid management, pain relief, shortness of breath) becomes even more important. Some patients subsequently receive radiotherapy to painful or obstructive areas.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._